High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice

2018 ◽  
Vol 132 (7) ◽  
pp. 759-776 ◽  
Author(s):  
Xiao Wang ◽  
Huarong Wang ◽  
Wei Liu ◽  
Zhiyuan Zhang ◽  
Yanhao Zhang ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Natriuretic Peptide ◽  
Polycystic Ovary ◽  
Germinal Vesicle ◽  
Ovary Syndrome ◽  
Oocyte Meiosis ◽  
Type C ◽  
High Level ◽  
Reproductive Aged Women ◽  
Insight Into

Polycystic ovary syndrome (PCOS), which is characterized by hyperandrogenism, is a complex endocrinopathy that affects the fertility of 9–18% of reproductive-aged women. However, the exact mechanism of PCOS, especially hyperandrogen-induced anovulation, is largely unknown to date. Physiologically, the natriuretic peptide type C/natriuretic peptide receptor 2 (CNP/NPR2) system is essential for sustaining oocyte meiotic arrest until the preovulatory luteinizing hormone (LH) surge. We therefore hypothesized that the CNP/NPR2 system is also involved in PCOS and contributes to arresting oocyte meiosis and ovulation. Here, based on a dehydroepiandrosterone (DHEA)-induced PCOS-like mouse model, persistent high levels of CNP/NPR2 were detected in anovulation ovaries. Meanwhile, oocytes arrested at the germinal vesicle stage correlated with persistent high levels of androgen and estrogen. We further showed that ovulation failure in these mice could be a result of elevated Nppc/Npr2 gene transcription that was directly increased by androgen (AR) and estrogen (ER) receptor signaling. Consistent with this, anovulation was alleviated by administration of either exogenous human chorionic gonadotropin (hCG) or inhibitors of AR or ER to reduce the level of CNP/NPR2. Additionally, the CNP/NPR2 expression pattern in the anovulated follicles was, to some extent, consistent with the clinical expression in PCOS patients. Therefore, our study highlights the important role an overactive CNP/NPR2 system caused by hyperandrogenism in preventing oocytes from maturation and ovulation in PCOS mice. Our findings provide insight into potential mechanisms responsible for infertility in women with PCOS.

scholarly journals Association analysis between the polymorphisms of HSD17B5 and HSD17B6 and risk of polycystic ovary syndrome in Chinese population

2015 ◽  
Vol 172 (3) ◽  
pp. 227-233 ◽  
Author(s):  
Rong Ju ◽  
Wei Wu ◽  
Juan Fei ◽  
Yufeng Qin ◽  
Qiuqin Tang ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Chinese Population ◽  
Chinese Women ◽  
Polycystic Ovary ◽  
Control Group ◽  
Model Assessment ◽  
Nucleotide Polymorphisms ◽  
Ovary Syndrome ◽  
Significant Difference ◽  
High Level

ObjectiveTo assess whether single nucleotide polymorphisms of HSD17B5 (AKR1C3) (rs1937845 and rs12529) and HSD17B6 (rs898611) are associated with polycystic ovary syndrome (PCOS) in a Chinese population.DesignA case–control study was conducted to investigate the relation between HSD17B5 and HSD17B6 polymorphisms and PCOS.MethodsIn this study, 335 patients with PCOS and 354 controls were recruited. The genotypes of HSD17B5 (rs1937845 and rs12529) and HSD17B6 (rs898611) were detected by the TaqMan method.Results and conclusionsWe found that the genotypic frequencies of the rs1937845 polymorphism were different in subjects with PCOS compared with control, with the CT genotype being more commonly found in patients with PCOS than in controls (P=0.005). We observed a significantly 1.74-fold higher risk of CT genotype in the polymorphism rs1937845 in women with PCOS vs the control group (adjusted odds ratio (OR), 1.74; 95% CI=1.19–2.54; P=0.005). A similar, significant 1.47-fold higher risk (adjusted OR, 1.47; 95% CI=1.07–2.03; P=0.018) was demonstrated for T allele of polymorphism rs1937845 associated with PCOS. In patients with PCOS, the rs12529 (G>C) and rs1937845 (C>T) polymorphisms were strongly associated with the high level of testosterone. The TT carriers of polymorphism rs1937845 had a significantly increased homeostatic model assessment-B% (HOMA-B%) (P=0.045) and that might be associated with the high risk of insulin resistance. However, no significant difference was found in genotype or allele distributions of the polymorphisms rs12529 of HSD17B5 and rs898611 of HSD17B6 between patients with PCOS and controls. Additionally, the two polymorphisms of HSD17B5 are associated with hyperandrogenemia in patients with PCOS. In conclusion, our findings showed a significant statistical association between HSD17B5 rs1937845 and PCOS risk in Chinese women. The CT genotype and T allele frequency are influenced significantly to a higher extent in patients with PCOS than controls. Further studies are needed to confirm the results and find out the exact molecular mechanism of the polymorphism on the risk of hyperandrogenemia and PCOS.

scholarly journals Metabolomic Insight into Polycystic Ovary Syndrome—An Overview

2020 ◽  
Vol 21 (14) ◽  
pp. 4853 ◽  
Author(s):  
Anna Rajska ◽  
Magdalena Buszewska-Forajta ◽  
Dominik Rachoń ◽  
Michał Jan Markuszewski
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Metabolic Pathways ◽  
Polycystic Ovary ◽  
Review Article ◽  
Endocrine Disorders ◽  
Crucial Aspect ◽  
Ovary Syndrome ◽  
Metabolic Markers ◽  
Insight Into ◽  
Potential Biomarkers

Searching for the mechanisms of the polycystic ovary syndrome (PCOS) pathophysiology has become a crucial aspect of research performed in the last decades. However, the pathogenesis of this complex and heterogeneous endocrinopathy remains unknown. Thus, there is a need to investigate the metabolic pathways, which could be involved in the pathophysiology of PCOS and to find the metabolic markers of this disorder. The application of metabolomics gives a promising insight into the research on PCOS. It is a valuable and rapidly expanding tool, enabling the discovery of novel metabolites, which may be the potential biomarkers of several metabolic and endocrine disorders. The utilization of this approach could also improve the process of diagnosis and therefore, make treatment more effective. This review article aims to summarize actual and meaningful metabolomic studies in PCOS and point to the potential biomarkers detected in serum, urine, and follicular fluid of the affected women.

Serum brain natriuretic peptide and C-reactive protein levels in adolescent with polycystic ovary syndrome

2012 ◽  
Vol 28 (8) ◽  
pp. 602-605 ◽  
Author(s):  
Rüya Deveer ◽  
Yaprak Engin-Üstün ◽  
Sema Uysal ◽  
Filiz Akın Su ◽  
Seval Sarıaslan ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Polycystic Ovary ◽  
C Reactive Protein ◽  
Ovary Syndrome ◽  
Protein Levels ◽  
Reactive Protein

Anti-Müllerian hormone as an indicator of reproductive health in women with obesity and concomitant polycystic ovary syndrome

2016 ◽  
Vol 88 (12) ◽  
pp. 41-44
Author(s):  
A K Durmanova ◽  
N K Otarbaev
Keyword(s):  
Body Mass Index ◽  
Lipid Metabolism ◽  
Reproductive Health ◽  
Polycystic Ovary Syndrome ◽  
Abdominal Obesity ◽  
Polycystic Ovary ◽  
Morphometric Parameters ◽  
Ovary Syndrome ◽  
Carbohydrate And Lipid Metabolism ◽  
Reproductive Aged Women

Aim. To investigate the ovarian reserve and a relationship between the level of anti-Müllerian hormone (AMH) with that of hormones in reproductive-aged women with abdominal obesity concurrent with and without polycystic ovary syndrome (PCOS). Subjects and methods. A total of 157 women aged 18 to 45 years with a body mass index (BMI) of more than 30 kg/m2 were examined. The 157 women with abdominal obesity were conventionally divided into 2 groups: 1) 20 with PCOS and 2) 137 without this condition. Morphometric parameters, the indicators of carbohydrate and lipid metabolism, and the levels of hormones, including AMH, were studied. Results. The patients with PCOS had statistically significantly elevated AMH levels (11.26±2.63 ng/ml; p

scholarly journals Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome

2016 ◽  
pp. 1
Author(s):  
Cenk Yasa ◽  
Özlem Dural ◽  
Ercan Bastu ◽  
Funda Güngör Uğurlucan
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Androgenic Alopecia ◽  
Ovary Syndrome ◽  
Cutaneous Manifestations ◽  
Insulin Sensitizers ◽  
Criteria For Diagnosis ◽  
Reproductive Aged Women ◽  
Topical Medications ◽  
Endocrine Abnormality

<p>PPolycystic ovary syndrome is the most common endocrine abnormality that affects reproductive-aged women. Diagnostic criteria of polycystic ovary syndrome have been established by different societies in recent years, and hyperandrogenism remains as one of the main criteria for diagnosis. Cutaneous manifestations of hyperandrogenism include hirsutism, acne and androgenic alopecia and are commonly observed in women with polycystic ovary syndrome. The major determinants of cutaneous manifestations are increased production of androgen and increased tissue availability. Cutaneous manifestations of hyperandrogenism are cosmetic problems, which produce significant emotional distress and psychological morbidity. Treatment includes a combination of combined oral contraceptives, antiandrogens, insulin sensitizers, gonadotropin releasing hormone agonists, topical medications, and cosmetic procedures. The diagnosis, management, and treatment approaches are described in detail in this review.</p>

Sign in / Sign up

Export Citation Format

Share Document